FR17C1009I2 - Agents therapeutiques pour reduire les niveaux d' hormone parathyroidienne - Google Patents
Agents therapeutiques pour reduire les niveaux d' hormone parathyroidienneInfo
- Publication number
- FR17C1009I2 FR17C1009I2 FR17C1009C FR17C1009C FR17C1009I2 FR 17C1009 I2 FR17C1009 I2 FR 17C1009I2 FR 17C1009 C FR17C1009 C FR 17C1009C FR 17C1009 C FR17C1009 C FR 17C1009C FR 17C1009 I2 FR17C1009 I2 FR 17C1009I2
- Authority
- FR
- France
- Prior art keywords
- therapeutic agents
- parathyroid hormone
- hormone levels
- reduce parathyroid
- reduce
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 102000003982 Parathyroid hormone Human genes 0.000 title 1
- 108090000445 Parathyroid hormone Proteins 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 239000000199 parathyroid hormone Substances 0.000 title 1
- 229960001319 parathyroid hormone Drugs 0.000 title 1
- 229940124597 therapeutic agent Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
- A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22969509P | 2009-07-29 | 2009-07-29 | |
| US25581609P | 2009-10-28 | 2009-10-28 | |
| US31363510P | 2010-03-12 | 2010-03-12 | |
| PCT/US2010/043792 WO2011014707A2 (en) | 2009-07-29 | 2010-07-29 | Therapeutic agents for reducing parathyroid hormone levels |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR17C1009I1 FR17C1009I1 (enrdf_load_stackoverflow) | 2017-04-21 |
| FR17C1009I2 true FR17C1009I2 (fr) | 2019-04-12 |
Family
ID=43527590
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR17C1009C Active FR17C1009I2 (fr) | 2009-07-29 | 2017-03-17 | Agents therapeutiques pour reduire les niveaux d' hormone parathyroidienne |
Country Status (29)
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103961686A (zh) | 2006-11-16 | 2014-08-06 | 凯制药公司 | 用于治疗甲状旁腺功能亢进和高钙血症的聚阳离子钙调节肽 |
| SG178143A1 (en) | 2009-07-29 | 2012-03-29 | Kai Pharmaceuticals Inc | Therapeutic agents for reducing parathyroid hormone levels |
| CA2791174C (en) | 2010-03-04 | 2015-11-17 | Ajinomoto Co., Inc. | Alkylamine derivative |
| WO2011108724A1 (ja) | 2010-03-04 | 2011-09-09 | 味の素株式会社 | 糖尿病又は肥満症の予防又は治療剤 |
| EP2551262A4 (en) | 2010-03-24 | 2014-01-15 | Ajinomoto Kk | GLUTAMATE DERIVATIVES OR SALTS THEREOF |
| WO2011126099A1 (ja) | 2010-04-02 | 2011-10-13 | 味の素株式会社 | 糖尿病又は肥満症の予防又は治療剤 |
| DK2717896T3 (en) * | 2011-06-08 | 2016-12-19 | Kai Pharmaceuticals Inc | Therapeutics for regulating phoshor serum |
| CN109985228A (zh) | 2011-11-10 | 2019-07-09 | 凯伊药品公司 | 拟钙剂及其使用方法 |
| EP2872160A4 (en) | 2012-04-17 | 2015-11-25 | Univ Brown | NERVO-PROTECTING COMPOSITION AND USE METHOD |
| US20200354428A9 (en) | 2013-06-23 | 2020-11-12 | Wisconsin Alumni Research Foundation | Analogues of parathyroid hormone (1-34) that function as agonists of the parathyroid hormone receptor-1 and display modified activity profiles |
| PE20210413A1 (es) | 2013-06-28 | 2021-03-04 | Amgen Inc | Formulacion liquida estable que comprende etelcalcetida (amg416), un agente tamponante y agente de tonicidad |
| DK3126373T3 (da) * | 2014-04-03 | 2020-05-04 | Amgen Inc | Fremgangsmåde til fremstilling af amg 416 |
| CN105504012A (zh) * | 2014-09-30 | 2016-04-20 | 深圳翰宇药业股份有限公司 | 一种多肽的制备方法 |
| WO2016065042A1 (en) | 2014-10-22 | 2016-04-28 | Extend Biosciences, Inc. | Therapeutic vitamin d conjugates |
| US9616109B2 (en) | 2014-10-22 | 2017-04-11 | Extend Biosciences, Inc. | Insulin vitamin D conjugates |
| AU2016238233B2 (en) * | 2015-03-26 | 2019-11-21 | Amgen Inc. | Solution phase method for preparing etelcalcetide |
| US9336841B1 (en) * | 2015-04-16 | 2016-05-10 | Taiwan Semiconductor Manufacturing Co., Ltd. | Pipeline register with data alignment therein |
| CN106928320B (zh) | 2015-12-31 | 2021-01-15 | 深圳翰宇药业股份有限公司 | 一种合成Etelcalcetide的方法 |
| CN106928321B (zh) * | 2015-12-31 | 2019-07-26 | 深圳翰宇药业股份有限公司 | 一种合成Etelcalcetide的方法 |
| WO2018044468A1 (en) * | 2016-08-30 | 2018-03-08 | Wisconsin Alumni Research Foundation | COMBINATION OF LOW DOSE 2-METHYLENE-19-NOR-(20S)-1α, 25-DIHYDROXYVITAMIN D3 AND CALCIMIMETICS TO TREAT SECONDARY HYPERPARATHYROIDISM |
| CN111601614A (zh) * | 2017-11-07 | 2020-08-28 | 阿尔法科制药有限责任公司 | 治疗和预防心脏病、心血管疾病及相关病症和症状的方法 |
| WO2019124411A1 (ja) | 2017-12-20 | 2019-06-27 | Ｅａファーマ株式会社 | 維持透析下の二次性副甲状腺機能亢進症の予防または治療用医薬組成物 |
| KR101933685B1 (ko) * | 2018-06-29 | 2018-12-28 | 주식회사 에스알바이오텍 | 약물이 코팅된 마이크로 니들 및 이의 제조방법 |
| AU2019370565A1 (en) * | 2018-11-02 | 2021-06-24 | Ampersand Biopharmaceuticals, Inc. | Management of risk of cation overload and electrolyte imbalance with topically applied buffers |
| WO2020204117A1 (ja) | 2019-04-03 | 2020-10-08 | Ｅａファーマ株式会社 | 安定性の良好な医薬組成物 |
| US20230041996A1 (en) * | 2019-12-09 | 2023-02-09 | Beijing Tuo Jie Biopharmaceutical Co. Ltd. | Calcium-sensing receptor agonist compound and application thereof |
| US20230223125A1 (en) * | 2020-05-04 | 2023-07-13 | University Of Louisville Research Foundation, Inc. | Artificial intelligence-based systems and methods for dosing of pharmacologic agents |
| KR20230066044A (ko) * | 2020-09-10 | 2023-05-12 | 샨시 마이콧 테크놀로지 컴퍼니 리미티드 | 이중특이적 융합 폴리펩타이드 화합물 |
| US11359134B2 (en) | 2020-10-19 | 2022-06-14 | Saudi Arabian Oil Company | Treatment fluids and methods for recovering hydrocarbons from a subterranean formation |
| CN117500820A (zh) * | 2021-06-08 | 2024-02-02 | 北京拓界生物医药科技有限公司 | 钙敏感受体激动剂化合物的盐酸盐及药物组合物和其应用 |
| WO2022257958A1 (zh) * | 2021-06-08 | 2022-12-15 | 北京拓界生物医药科技有限公司 | 一种钙敏感受体激动剂的组合物及其应用 |
| CN120225181A (zh) | 2022-09-30 | 2025-06-27 | 延伸生物科学股份有限公司 | 长效甲状旁腺激素 |
| WO2025054169A1 (en) * | 2023-09-05 | 2025-03-13 | Wake Forest University Health Sciences | Compositions and methods for topical treatment |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5869473A (en) * | 1988-08-02 | 1999-02-09 | Bone Care International, Inc. | Method for treating and preventing hyperparathyroidism |
| US5602116A (en) | 1988-08-02 | 1997-02-11 | Bone Care International, Inc. | Method for treating and preventing secondary hyperparathyroidism |
| CA1333616C (en) | 1989-03-09 | 1994-12-20 | Hector F. Deluca | 19-nor-vitamin d compounds |
| US5246925A (en) | 1989-03-09 | 1993-09-21 | Wisconsin Alumni Research Foundation | 19-nor-vitamin D compounds for use in treating hyperparathyroidism |
| US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
| AU9131091A (en) | 1990-11-07 | 1992-06-11 | Scripps Research Institute, The | Peptides that inhibit platelet binding of adhesion molecules |
| US6031003A (en) * | 1991-08-23 | 2000-02-29 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
| US5814603A (en) * | 1992-06-12 | 1998-09-29 | Affymax Technologies N.V. | Compounds with PTH activity |
| US5716981A (en) | 1993-07-19 | 1998-02-10 | Angiogenesis Technologies, Inc. | Anti-angiogenic compositions and methods of use |
| CA2145214A1 (en) | 1995-02-28 | 1996-08-29 | Rick E. Preddie | Agents for pre-symptomatic diagnosis, prevention and cure huntington's disease (hd) in humans |
| US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
| US5688489A (en) * | 1995-09-15 | 1997-11-18 | Resolution Pharmaceuticals, Inc. | Non-receptor mediated imaging agents |
| WO1998004591A1 (en) | 1996-07-31 | 1998-02-05 | The General Hospital Corporation | Novel parathyroid hormone-related peptide analogs |
| US5895368A (en) * | 1996-09-23 | 1999-04-20 | Medisystems Technology Corporation | Blood set priming method and apparatus |
| US6165977A (en) * | 1996-10-18 | 2000-12-26 | Board Of Trustees Of The Leland Stanford Junior University | Isozyme-specific activators of protein kinase C methods and compositions |
| WO1998033812A1 (en) * | 1997-02-05 | 1998-08-06 | Brigham And Women's Hospital, Inc. | Mast cell protease peptide inhibitors |
| UA62967C2 (en) | 1997-05-14 | 2004-01-15 | Aventis Pharm Prod Inc | Peptide analogs of parathyroid hormons |
| EP0975370B9 (en) * | 1997-05-21 | 2004-11-03 | The Board Of Trustees Of The Leland Stanford Junior University | Composition and method for enhancing transport across biological membranes |
| US6258774B1 (en) | 1998-03-19 | 2001-07-10 | University Of Medicine And Dentistry Of New Jersey | Carrier for in vivo delivery of a therapeutic agent |
| US7399489B2 (en) | 1999-01-14 | 2008-07-15 | Amylin Pharmaceuticals, Inc. | Exendin analog formulations |
| JP2000336099A (ja) * | 1999-05-27 | 2000-12-05 | Sekisui Chem Co Ltd | ペプチド及びｃ型肝炎抗体検出用試薬 |
| US6051567A (en) | 1999-08-02 | 2000-04-18 | Abbott Laboratories | Low oxygen content compositions of 1α, 25-dihydroxycholecalciferol |
| US6274169B1 (en) | 1999-08-02 | 2001-08-14 | Abbott Laboratories | Low oxygen content compostions of 1α, 25-dihydroxycholecalciferol |
| US20020068342A1 (en) * | 2000-02-09 | 2002-06-06 | Rami Khosravi | Novel nucleic acid and amino acid sequences and novel variants of alternative splicing |
| AU2001278956B2 (en) | 2000-07-18 | 2007-04-05 | Genzyme Corporation | Stabilized 1alpha-hydroxy vitamin d |
| DE10041126A1 (de) | 2000-08-22 | 2002-04-04 | Aventis Res & Tech Gmbh & Co | DNA-bindende Peptiddomänen und ein Verfahren zur Bereitstellung solcher Domänen |
| US20080249016A1 (en) * | 2000-09-18 | 2008-10-09 | Sanos Bioscience A/S | Use of GLP-2 in a combination treatment for bone-related disorders |
| US20020168354A1 (en) * | 2000-11-10 | 2002-11-14 | Daria Mochly-Rosen | psiepsilonRack peptide composition and method for protection against tissue damage due to ischemia |
| WO2002057413A2 (en) * | 2001-01-18 | 2002-07-25 | The Board Of Trustees Of The Leland Stanford Junior University | Peptides for activation and inhibition of delta pkc |
| AU2002240312A1 (en) | 2001-02-08 | 2002-08-19 | Pankaj Paranjp | Enhanced oral and transcompartmental delivery of therapeutic or diagnostic agents using polymer conjugates |
| US20030036627A1 (en) * | 2001-02-16 | 2003-02-20 | Montelaro Ronald C. | Virus derived antimicrobial peptides |
| ES2527339T3 (es) | 2001-02-23 | 2015-01-23 | Polyphor Ltd. | Peptidomiméticos fijados a patrón con actividad antimicrobiana |
| US6790833B2 (en) | 2001-08-08 | 2004-09-14 | The Research Foundation Of The State University Of New York | Antifungal and antibacterial agents |
| US6998404B2 (en) | 2001-08-08 | 2006-02-14 | Genomed, Llc | Treatment or prevention of acute renal failure |
| US7060023B2 (en) | 2001-09-25 | 2006-06-13 | The Foundry Inc. | Pericardium reinforcing devices and methods of using them |
| US7037897B2 (en) * | 2001-10-31 | 2006-05-02 | Abbott Laboratories | TRI-, TETRA-, and penta-peptides having antiangiogenic activity |
| JP2005287302A (ja) | 2002-04-03 | 2005-10-20 | Haruhiko Fujiwara | ポリペプチドの架橋方法 |
| EP1576141A4 (en) * | 2002-05-14 | 2006-03-22 | Bristol Myers Squibb Co | NEW HUMAN G-PROTEIN-COUPLED RECEPTORS CODING POLYNUCLEOTIDE AND SPLEISS VARIANTS THEREOF |
| WO2005049647A2 (en) | 2003-11-05 | 2005-06-02 | Pevion Biotech Ltd. | Compositions comprising melittin-derved peptides and methods for the potentiation of immune responses against target antigens |
| CA2549052A1 (en) | 2003-12-11 | 2005-06-30 | The Board Of Trustees Of The Leland Stanford Junior University | Isozyme-specific antagonists of protein kinase c |
| WO2005072340A2 (en) | 2004-01-27 | 2005-08-11 | Compugen Ltd. | Novel polynucleotides encoding polypeptides and methods using same |
| WO2006015005A2 (en) * | 2004-07-27 | 2006-02-09 | Genzyme Corporation | Use of thyrotropin for regeneration of bone |
| US7265092B2 (en) * | 2004-09-30 | 2007-09-04 | Kai Pharmaceuticals, Inc. | Pharmaceutical formulation |
| DE102005013846A1 (de) | 2005-03-24 | 2006-10-05 | Ganymed Pharmaceuticals Ag | Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie |
| KR100687932B1 (ko) * | 2005-08-09 | 2007-02-27 | 삼성전자주식회사 | 영상표시장치 및 영상표시방법 |
| JP2009511426A (ja) * | 2005-08-30 | 2009-03-19 | アコロジックス インコーポレイティッド | ミネラルおよび骨格代謝の調節 |
| CN103961686A (zh) * | 2006-11-16 | 2014-08-06 | 凯制药公司 | 用于治疗甲状旁腺功能亢进和高钙血症的聚阳离子钙调节肽 |
| CA2675665C (en) | 2007-01-19 | 2018-02-13 | Kai Pharmaceuticals, Inc. | Modifications of peptide compositions to increase stability and delivery efficiency |
| AU2008308679B2 (en) * | 2007-10-02 | 2015-01-29 | Marina Biotech, Inc. | Lipopeptides for delivery of nucleic acids |
| EP2229473A4 (en) | 2007-12-07 | 2011-02-02 | Steven A Goldstein | IDENTIFICATION OF TOXIN LIGANDS |
| US20090318351A1 (en) * | 2008-03-12 | 2009-12-24 | Kevin Grimes | Method of treating acute st-elevation myocardial infarction with a delta pkc antagonist |
| SG178143A1 (en) | 2009-07-29 | 2012-03-29 | Kai Pharmaceuticals Inc | Therapeutic agents for reducing parathyroid hormone levels |
| DK2717896T3 (en) * | 2011-06-08 | 2016-12-19 | Kai Pharmaceuticals Inc | Therapeutics for regulating phoshor serum |
| CN109985228A (zh) | 2011-11-10 | 2019-07-09 | 凯伊药品公司 | 拟钙剂及其使用方法 |
-
2010
- 2010-07-29 SG SG2012006185A patent/SG178143A1/en unknown
- 2010-07-29 SM SM20190307T patent/SMT201900307T1/it unknown
- 2010-07-29 US US12/846,724 patent/US8999932B2/en active Active
- 2010-07-29 PT PT108050782T patent/PT2459208T/pt unknown
- 2010-07-29 PL PL16190682T patent/PL3192520T3/pl unknown
- 2010-07-29 KR KR1020127004785A patent/KR101781841B1/ko active Active
- 2010-07-29 CN CN201080045024.9A patent/CN102711789B/zh active Active
- 2010-07-29 SI SI201031894T patent/SI3192520T1/sl unknown
- 2010-07-29 HU HUE16190682A patent/HUE043838T2/hu unknown
- 2010-07-29 SM SM201700014T patent/SMT201700014B/it unknown
- 2010-07-29 EP EP20209086.6A patent/EP3808363B1/en active Active
- 2010-07-29 ES ES10805078.2T patent/ES2607954T3/es active Active
- 2010-07-29 CN CN201710873189.9A patent/CN107674114B/zh active Active
- 2010-07-29 TW TW099125105A patent/TWI520744B/zh active
- 2010-07-29 AU AU2010278897A patent/AU2010278897B2/en active Active
- 2010-07-29 BR BR112012002143A patent/BR112012002143B8/pt active IP Right Grant
- 2010-07-29 EP EP10805078.2A patent/EP2459208B1/en active Active
- 2010-07-29 CA CA2769525A patent/CA2769525C/en active Active
- 2010-07-29 SI SI201031337A patent/SI2459208T1/sl unknown
- 2010-07-29 HU HUE10805078A patent/HUE030960T2/en unknown
- 2010-07-29 NZ NZ597922A patent/NZ597922A/en unknown
- 2010-07-29 DK DK16190682.1T patent/DK3192520T3/da active
- 2010-07-29 PT PT16190682T patent/PT3192520T/pt unknown
- 2010-07-29 LT LTEP10805078.2T patent/LT2459208T/lt unknown
- 2010-07-29 WO PCT/US2010/043792 patent/WO2011014707A2/en active Application Filing
- 2010-07-29 SG SG10201406921SA patent/SG10201406921SA/en unknown
- 2010-07-29 HR HRP20161614TT patent/HRP20161614T1/hr unknown
- 2010-07-29 DK DK10805078.2T patent/DK2459208T3/en active
- 2010-07-29 MX MX2012001213A patent/MX2012001213A/es active IP Right Grant
- 2010-07-29 RU RU2012107428A patent/RU2557654C3/ru active
- 2010-07-29 LT LTEP16190682.1T patent/LT3192520T/lt unknown
- 2010-07-29 SM SM20170014T patent/SMT201700014T1/it unknown
- 2010-07-29 JP JP2012523061A patent/JP5270799B2/ja active Active
- 2010-07-29 EP EP22193946.5A patent/EP4154900B1/en active Active
- 2010-07-29 EP EP16190682.1A patent/EP3192520B1/en active Active
- 2010-07-29 PL PL10805078T patent/PL2459208T3/pl unknown
- 2010-07-29 ES ES16190682T patent/ES2729051T3/es active Active
- 2010-07-29 EP EP19159337.5A patent/EP3539555B1/en active Active
-
2012
- 2012-01-26 IL IL217749A patent/IL217749A/en active Protection Beyond IP Right Term
- 2012-01-30 ZA ZA2012/00726A patent/ZA201200726B/en unknown
- 2012-02-02 US US13/365,213 patent/US8377880B2/en active Active
-
2013
- 2013-02-18 US US13/769,744 patent/US9278995B2/en active Active
- 2013-05-09 JP JP2013099331A patent/JP5764613B2/ja active Active
-
2014
- 2014-02-10 JP JP2014023488A patent/JP2014094967A/ja active Pending
-
2015
- 2015-03-04 US US14/639,020 patent/US9567370B2/en active Active
-
2016
- 2016-02-08 US US15/018,567 patent/US9701712B2/en active Active
- 2016-12-27 CY CY20161101349T patent/CY1118388T1/el unknown
-
2017
- 2017-01-09 US US15/402,133 patent/US20170114095A1/en not_active Abandoned
- 2017-03-01 HU HUS1700008 patent/HUS1700008I1/hu unknown
- 2017-03-09 LU LU00008C patent/LUC00008I2/fr unknown
- 2017-03-10 LT LTPA2017007C patent/LTC2459208I2/lt unknown
- 2017-03-16 CY CY2017010C patent/CY2017010I1/el unknown
- 2017-03-17 FR FR17C1009C patent/FR17C1009I2/fr active Active
- 2017-05-05 NO NO2017021C patent/NO2017021I1/no unknown
- 2017-06-21 US US15/629,536 patent/US10280198B2/en active Active
-
2019
- 2019-03-11 US US16/298,902 patent/US20190194252A1/en not_active Abandoned
- 2019-05-17 HR HRP20190923TT patent/HRP20190923T1/hr unknown
- 2019-05-31 CY CY20191100579T patent/CY1121922T1/el unknown
-
2020
- 2020-09-02 US US17/010,773 patent/US20200399309A1/en not_active Abandoned
-
2022
- 2022-10-04 US US17/960,060 patent/US20240116983A1/en not_active Abandoned
-
2025
- 2025-01-16 US US19/025,984 patent/US20250163103A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FR17C1009I2 (fr) | Agents therapeutiques pour reduire les niveaux d' hormone parathyroidienne | |
| FR2949669B1 (fr) | Mecanisme d'epaule pour orthese | |
| EP2381906A4 (en) | WATER-RESISTANT BANDAGE | |
| EP2666475A4 (en) | THERAPEUTIC ACTIVE AGAINST HAIR LOSS | |
| FR2954857B3 (fr) | Accumulateur ion-lithium specifique pour l'allumage de motos | |
| BR112012002519A2 (pt) | "pesticidas mesoiônicos" | |
| EP2398483A4 (en) | Oxyntomodulin Analogs | |
| BR112012010595A2 (pt) | "dispensdor" | |
| EP2442414A4 (en) | Waterproof box | |
| EP2554919A4 (en) | MODULAR WATER SAVING SYSTEM | |
| EP2656872A4 (en) | ELECTRODE PAD FOR IONTOPHORESIS | |
| EP2600944A4 (en) | ANTI GRAVITY FULL BODY WORKOUT CLOTHES | |
| EP2408796A4 (en) | APOLIPOPROTEIN B-TARGETINE FOR REDUCING APOLIPOPROTEIN C-III | |
| IT1395915B1 (it) | Potabilizzatore d'acqua | |
| EP2442415A4 (en) | WATERPROOF BOX | |
| SMT201600041B (it) | Agenti terapeutici 713 | |
| IT1393777B1 (it) | Composizione per l'igiene intima | |
| EP2486925A4 (en) | Therapeutic agent for cerebral infarction | |
| EP2624842A4 (en) | USE OF HYALURONAN TO PROMOTE AN ANGIOGENESIS | |
| EP2615317A4 (en) | HINGE MECHANISM | |
| EP2580287A4 (en) | AGAINST CRATER FOR AN ELECTRIC COATING COMPOSITION | |
| EP2753626A4 (en) | LLP2A-BISPHOSPHONATE CONJUGATES FOR THE TREATMENT OF OSTEOPOROSIS | |
| EP2501714A4 (en) | HETEROPEPTIDES FOR REDUCING NON-SPECIFIC ADSORPTION | |
| BRPI1009730A2 (pt) | "recipiente" | |
| EP2460524A4 (en) | MEDICAL COMPOSITION FOR IDE IONTOPHORESIS |